alleging they illegally drove up drug prices. Apart from pharmacy benefit managers, the FTC says Eli Lilly, Sanofi and Novo Nordisk have control over the insulin market, and all three companies ...

In its complaint, the FTC alleges that PBMs followed a “chase-the-rebate strategy,” which led to soaring insulin list prices and made it harder for Americans to get the crucial medication ...

(AP) - The federal government is suing some big pharmacy benefit managers over a system of drug rebates that regulators say has made the price of insulin soar for diabetic ... and negotiate rebates ...

The FTC believes that the PBMs participated in unjust competition and practices, incentivizing manufacturers to increase insulin list prices. “Express Scripts intends to vigorously defend itself to ...

No matter what happens in this election, the government should work for the people. The government may not be perfect, but it ...

The FTC alleges that these companies engaged in anticompetitive and unfair rebating practices that have artificially inflated the list prices of insulin drugs, restricted patient access to lower ...

(AP) - The federal government is suing some big pharmacy benefit managers over a system of drug rebates that regulators say has made the price of insulin ... the drug prices. The FTC said the ...